Combined MRI/MRS Protocol for Specificity Improvement in Breast Cancer Detection

of the whole breast with the suspicious lesion(s), with 30 o flip angle, TE = 3.8 ms, TR = 9 ms, 3-5 mm slice thickness, 24 cm FOV and 64x256 matrix size. Usually each frame included 18-26 slices and the acquisition time for each frame was less than 16 sec. Gd contrast agent (0.1 mmol/kg dose) was delivered at 2 cc/sec by IV injection at the start of the second frame acquisition. The images of the first frame were subtracted from images of every frame. Rapid contrast enhancement in lesions with signal intensity reaching plateau by the fourth frame was defined as positive finding. Any enhancement with continuous rising of signal intensity through eight frames or no enhancement was defined as negative finding. The study was discontinued for patients with negative findings. Patients with positive findings, with further consent, continued to undergo 1 H MRS and perfusion MRI examinations. Single-voxel proton spectrum was collected from the enhanced lesion with a PRESS sequence, TE = 135 ms, TR = 2 s, and 128 scan averages. Perfusion MRI was performed on a 5-mm single sagittal slice containing the enhanced lesion with a T2*-weighted FLASH sequence, 10 o flip angle, TE = 35 ms, TR = 54 ms, 24 cm FOV, 92x256 matrix size, and 40 frames. IV injection of Gd contrast agent (0.1 mmol/kg) was carried out at 4 cc/sec during perfusion MRI acquisition. The detection of an apparent Cho peak (S/N > 2) at 3.23 ppm was defined as positive finding for the MRS study. The relative blood volume map was generated from the perfusion imaging data. The striking enhancement in the lesion area on the map compared to normal tissue area was defined as positive finding for the perfusion MRI study. Results Fig. 1a shows an image obtained from the DCE MRI experiment. This image was the result of subtraction of the first frame image from the third frame image, revealing an enhanced lesion. The placement of a spectroscopic voxel, encompassing the enhanced area, is also shown in the figure. Fig. 1b shows the time course of image signal intensity from the enhanced lesion. The intensity reached plateau by the fourth frame, implying positive findings of DCE MRI for this patient. Fig. 2 shows a representative magnified proton spectrum collected from an enhanced lesion of a patient with positive DCE MRI findings. An apparent Cho peak was detected, indicating positive MRS findings. Fig. 3 shows the relative blood volume map of a patient whose DCE MRI and MRS findings were both positive. The strong enhancement was seen in the lesion area, revealing high vascularity of the tumor and positive findings for the perfusion MRI study. The MR and pathology results of the 87 patients are summarized in the Table. Based on the pathology results, there were no false negative findings from DCE MRI studies, showing 100% sensitivity of this method. 21 out of 60 patients with positive DCE MRI findings turned out to have benign lesions, resulting in 56% specificity of this method. With the addition of 1 H MRS data, the specificity in detection of breast malignancy improves to 85%. With further addition of perfusion MRI results, excluding the data from two patients who had DCE MRI and MRS but declined perfusion MRI, the specificity improves to 100%. Discussion This study shows that while DCE MRI has very high sensitivity in diagnosis of breast cancer, its specificity is unsatisfactory. The combined MRI/MRS protocol of DCE MRI, 1 H MRS and perfusion MRI techniques substantially improves specificity in detection of breast malignancy and may help to reduce unnecessary biopsies following positive mammograms. It appeared that the false positive findings of 1 H MRS studies, which were mostly from fibroadenomas, could be corrected by taking into account the perfusion MRI data. With its technology easy for implementation and its data easy for